These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7685909)

  • 1. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
    Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
    Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
    Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
    Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
    Chen L
    Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
    Baskar S; Glimcher L; Nabavi N; Jones RT; Ostrand-Rosenberg S
    J Exp Med; 1995 Feb; 181(2):619-29. PubMed ID: 7836917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.
    Behar SM; Porcelli SA; Beckman EM; Brenner MB
    J Exp Med; 1995 Dec; 182(6):2007-18. PubMed ID: 7500046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C; Marley J; Loh S; Robinson B; Garlepp M
    Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
    Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
    Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
    Ramarathinam L; Castle M; Wu Y; Liu Y
    J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.
    Li Y; Hellstrom KE; Newby SA; Chen L
    J Exp Med; 1996 Feb; 183(2):639-44. PubMed ID: 8627175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An autologous self-antigen differentially regulates expression of I-A glycoproteins and B7 costimulatory molecules on CD4- CD8- T helper cells.
    Walker MR; White GA; Nardella JP; Mannie MD
    J Leukoc Biol; 1999 Jul; 66(1):120-6. PubMed ID: 10410999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.
    Wilson JL; Cunningham AC; Kirby JA
    Immunology; 1995 Nov; 86(3):325-30. PubMed ID: 8550066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant adenovirus coexpressing covalent peptide/MHC class II complex and B7-1: in vitro and in vivo activation of myelin basic protein-specific T cells.
    Chen J; Huber BT; Grand RJ; Li W
    J Immunol; 2001 Aug; 167(3):1297-305. PubMed ID: 11466346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
    Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of alloreactivity of melanoma by transduction with B7.1.
    Brady MS; Lee F; Eckels DD; Ree SY; Latouche JB; Lee JS
    J Immunother; 2000; 23(3):353-61. PubMed ID: 10838664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.
    Gimmi CD; Freeman GJ; Gribben JG; Gray G; Nadler LM
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6586-90. PubMed ID: 7688125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration.
    Lang S; Whiteside TL; Lebeau A; Zeidler R; Mack B; Wollenberg B
    Arch Otolaryngol Head Neck Surg; 1999 Jan; 125(1):82-8. PubMed ID: 9932594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
    Armstrong TD; Clements VK; Ostrand-Rosenberg S
    J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.